IP Library Granted Patent US 10,406,029
Granted Patent B2
US 10,406,029 · App. 14/881,100 · Granted Sep 10, 2019

Ocular system with anchoring implant and therapeutic agent

Inventors: Hosheng Tu (Newport Coast, CA); Jason Artof (Westlake Village, CA); David Steven Haffner (Mission Viejo, CA); Gregory T. Smedley (Aliso Viejo, CA); Barbara A. Niksch (Capistrano Beach, CA)
Assignee: Glaukos Corporation
A61F9/00781A61F9/0017A61K31/215A61F2220/0008A61F2230/0069A61F2250/0067
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,406,029
App. No.
14/881,100
Granted
Sep 10, 2019
Kind
B2
Abstract

Ocular implants, delivery devices and methods for treating ocular disorders are disclosed. One method involves inserting an implant on one side of an eye. The implant has an anchor on a distal end portion and an outlet opening that is disposed proximal of the anchor. The implant is advanced across the eye to the other side of the eye. The anchor is inserted into eye tissue on the other side of the eye. A therapeutic agent is eluted using the implant.

Claims (17)

1. An implant for treating an ocular disorder, the implant comprising:

a seat comprising a generally elongate tubular member having a proximal portion and a distal portion, configured to be positioned in an anterior chamber of an eye;

a therapeutic drug to be eluted from the implant; and

a base portion comprising a shank and an anchor having a sharp end, wherein the anchor is attached to a distal portion of the seat through the shank, the anchor disposed at a distal-most portion of the base portion and being adapted to penetrate only partially into a sclera of the eye and secure the implant in the eye, wherein the anchor is solid;

wherein a cross-sectional area of the shank is smaller than a cross-sectional area of the seat;

wherein at least a portion of the shank is dimensioned to reside in Schlemm's canal.

2. The implant of claim 1 wherein a cross-sectional area of the base portion is smaller than a cross-sectional area of the seat.

3. The implant of claim 1 wherein at least a portion of the base portion is shaped and sized to be received in Schlemm's canal of the eye.

4. The implant of claim 1 wherein the therapeutic agent is an anti-glaucoma drug.

5. The implant of claim 1 wherein the seat comprises a bottom surface adapted to rest against a trabecular meshwork of an eye.

6. The implant of claim 5 wherein the bottom surface of seat comprises a textured surface.

7. The implant of claim 1 further comprising an inlet opening in the proximal portion.

8. The implant of claim 7 wherein the implant further comprises an outlet in fluid communication with the inlet opening.

9. The implant of claim 8 wherein the outlet is disposed proximal of the anchor.

10. The implant of claim 1 wherein the implant further comprises a standoff disposed to space the outlet from a wall of Schlemm's canal.

11. The implant of claim 1 wherein the anchor comprises a conical shape or a screw.

12. The implant of claim 1 wherein the tubular member is solid-walled.

Continuity (10)
Continuation 13399760 · Feb 17, 2012
Continuation 12246448 · Oct 6, 2008
Division 11083713 · Mar 18, 2005
Continuation In Part 10634213 · Aug 5, 2003
Continuation In Part 10118578 · Apr 8, 2002
Continuation In Part 10667580 · Sep 22, 2003
Continuation In Part 11598542 · Nov 13, 2006
Continuation 10118578 · Apr 8, 2002
Provisional Application 60281973 · Apr 7, 2001
Related Publication 20160100983A1 · Apr 14, 2016
Cited By (21)
US 1,137,672 US 12,186,237 US 12,201,555 US 12,201,557 US 12,208,034 US 12,226,308 US 12,279,822 US 12,343,288 US 12,376,989 US 12,414,798 US 12,419,783 US 12,427,057 US 12,478,503 US 12,478,504 US 12,514,750 US 12,544,258 US 12,575,972 US 12,589,025 US 12,599,497 US 12,667,486 US 12,702,294